Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Your browser is not supported
Switch to Chrome, Edge, Firefox or Safari
Gives patients information on buprenorphine and medication-assisted treatment for opioid addiction. Describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
Buprenorphine Treatment: Facts (Cambodian/Khmer)
File Type: PDF
File Size: 596 KB
The fourth supplemental resource to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and preparing to deliver.
This document examines treatment issues for both adult survivors of child abuse or neglect and adults in treatment who may be abusing or neglecting their own children.
This guide was drawn from HEALing Communities Study (HCS) learnings to-date and expert insights to provide guidance regarding implementation of ORCCA menu strategies.
Designed to help women deal with child abuse issues that might arise during treatment for alcohol abuse or drug abuse. Defines child abuse, lists symptoms of abuse, and suggests how counselors can help with coping and healing.
Read key findings from the 2021 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment. Metrics in the report cover the civilian, noninstitutionalized US population ages 12 and older. Estimates are presented by age group and by race/ethnicity for selected measures. Unlike other NSDUH Annual National Reports, the 2021 report has no discussion of trends over time, because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.
This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.
